期刊文献+

雄黄类抗癌制剂的专利研究进展 被引量:7

Research of Anticancer Realgar Preparations from Perspective of Patent
原文传递
导出
摘要 以专利为视角分析雄黄类抗癌制剂的研究进展,为雄黄抗肿瘤药物的研发提供借鉴与参考。在IncoPat数据库中以关键词加IPC分类号进行专利检索,人工去噪后共72件雄黄类抗癌制剂专利纳入研究范围,定量分析上述专利的申请趋势、申请类型和专利权人的相关信息,并以专利申请时间为线索对重点专利进行技术要点梳理。得到结果,①雄黄类抗癌制剂的专利类型以产品专利为主,其技术创新历经雄黄复方制剂研发、雄黄单方制剂研发、纳米雄黄制备方法研发、雄黄微生物浸出物研发、雄黄复方提取物制剂研发、复方纳米雄黄制剂研发及雄黄多晶型结构研发。②纳米雄黄制剂、雄黄微生物浸出制剂、雄黄新晶型制剂及雄黄复方制剂的开发是雄黄类抗癌制剂的当前研究热点。③不同制备工艺纳米雄黄的生物学效应和毒性的比较、纳米雄黄在抗肿瘤应用中的最佳粒径选择、雄黄微生物浸出制剂的成药性研究、高稳定性能的As4S4新晶型发现以及已上市雄黄抗癌制剂的二次开发是雄黄类抗癌制剂的未来发展方向。 To review the research progress of anticancer realgar preparations from the perspective of patent,in order to provide a reference for the research of new antitumor realgar drugs. IncoPat database was retrieved with keywords plus IPC classification number. Original data and 72 patents of anti-cancer realgar preparations were obtained and included after artificial denoising. The quantitative analysis was made on the information about application trends,application types and patentee. The technical points of representative patents were summarized. ① The patent types of anticancer realgar preparations are mainly product patents. Its technological innovation has undergone the development of realgar compound agents,arsenic sulfide single agents,nanometer products of realgar agents,bioleaching of realgar preparations,compound realgar extract preparations,compound nano realgar preparations and arsenic sulfide polymorphic crystalline structure. ② Nano realgar agents,realgar bioleaching preparations,new crystalline type realgar preparations and realgar compound preparations. ③ The following studies should be strengthened in the future,involving the comparison of biological effects and toxicity of nano realgar preparations of different preparation processes,the selection of optimal particle size,the druggability of realgar bioleaching preparations,the discovery of new As4S4 crystalline forms and the secondary development of anticancer realgar preparations.
作者 康琪 黄倩倩 曾洁 瞿礼萍 邹文俊 KANG Qi;HUANG Qian-qian;ZENG Jie;QU Li-ping;ZOU Weng-jun(School of Pharmacy,Chengdu University of Traditional Chinese Medicine(TCM),Chengdu 611137,China;Sichuan College of TCM,Mianyang 621000,China)
出处 《中国实验方剂学杂志》 CAS CSCD 北大核心 2020年第23期226-234,共9页 Chinese Journal of Experimental Traditional Medical Formulae
基金 四川省哲学社会科学重点研究基地四川医事卫生法治研究中心项目(YF18-Q15)。
关键词 雄黄 硫化砷 抗癌 肿瘤 专利 realgar arsenic sulfide anticancer tumor patent
  • 相关文献

参考文献25

二级参考文献259

共引文献437

同被引文献77

引证文献7

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部